Search

Your search keyword '"Tonini G."' showing total 2,341 results

Search Constraints

Start Over You searched for: Author "Tonini G." Remove constraint Author: "Tonini G."
2,341 results on '"Tonini G."'

Search Results

102. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene

106. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

107. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

108. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

109. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

110. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

112. COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables

113. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer

116. Hypogonadism and pubertal development in Prader-Willi syndrome

118. Analysis of cell cycle regulator proteins in non-small cell lung cancer

128. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

131. Structural skin changes in elderly people investigated by reflectance confocal microscopy

132. P-66 Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population

136. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

149. 220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

Catalog

Books, media, physical & digital resources